LifeStance Health Gr Bolsa (NASDAQ: LFST)

LifeStance Health Gr (NASDAQ:LFST) Bolsa

LifeStance Health Gr

LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.

LifeStance Health Group

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Group Inc

Earnings

News

Servotronics Q4 EPS From Cont. Ops. $(0.50) Down From $0.15 YoY, Sales $9.8M Down From $12.3M YoY

WIIM

SGMO

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Under the terms of the new Contract Manufacturing Agreement, effective as of March 17, 2025, AVITA Medical is to manufacture PermeaDerm at its state-of-the-art manufacturing facility in Ventura, California.&nbsp;

RCEL

AVITA Medical Enters New Contract Manufacturing Agreement For PermeaDerm Biosynthetic Wound Matrix, Along With Amendment To Existing Exclusive Distribution Deal With Stedical Scientific

2025 Financial Guidance
<ul>
<li>Management expects revenue for the first half of 2025 to be approximately $6 million. Management expects annual revenue growth for the full year 2025 to be 20% to 30% over 2024.</li>
<li>Management expects cash burn for the full year 2025 to be approximately $25 to 27 million, representing a 32% decline at the midpoint as compared to 2024.</li>
</ul>

Guidance

HYPR

Hyperfine Expects Revenue For The First Half Of 2025 To Be ~$6M; Expects Annual Revenue Growth For The Full Year 2025 To Be 20% To 30% Over 2024; Expects Cash Burn For The FY25 To Be ~$25M-$27M, Representing A 32% Decline At The Midpoint As Compared To 2024.

Earnings Beats

Metagenomi FY 2024 GAAP EPS $(2.36) Beats $(2.48) Estimate, Collaboration Revenue $52.295M

Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 6.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $2.32 million which missed the analyst consensus estimate of $3.00 million by 22.63 percent. This is a 13.59 percent decrease over sales of $2.69 million the same period last year.

Earnings Misses

Hyperfine Q4 EPS $(0.14), Inline, Sales $2.32M Miss $3.00M Estimate

Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate <a href="https://www.benzinga.com//node/44352934">atopic dermatitis</a>.
What To Know: This approval comes after data from phase 3 clinical trials showed that 90% of patients experienced symptom improvement within four weeks and 69% achieved at least a 50% reduction in disease severity.
Additionally, the cream met its primary endpoint in the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials, showing significant improvements as early as Week 1.
A recent survey by the Eczema Society of Canada revealed that 45% of Canadians with moderate atopic dermatitis reported itching negatively impacted their mental health. Furthermore, 69% said it heightened stress, and 62% experienced lasting scarring from scratching.
&#8220;We are proud to offer Canadians as young as six years old a new steroid-free option for managing atopic dermatitis that is grounded in both patient needs and clinical evidence,&#8221; said Jamie Lewis, vice president and general manager, Arcutis Canada.
 &#8220;Zoryve cream&nbsp;represents our commitment to providing innovative solutions that address the key challenges faced by patients and healthcare providers. We are grateful to the patients and investigators who participated in the clinical trials, as their contributions have made this achievement possible.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44362342/will-bitcoin-go-up-if-donald-trump-eliminates-income-tax">Will Bitcoin Go Up If Donald Trump Eliminates Income Tax For Americans Making Less Than $150,000?</a>
ARQT Price Action: Arcutis closed 12.31% higher at $16.42 on Monday, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Photo: Shutterstock

Biotech

Health Care

Movers

ARQT

What's Going On With Arcutis Biotherapeutics Stock Monday?

PURE

PURE Bioscience Q2 2025 EPS ($0.01) In-Line YoY; Revenue $391K Up From $325K YoY.

Buybacks

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand Announces Additional $50M Share Repurchase Authorization

Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of the Former Parent.
Net loss was $93.6 million during the fourth quarter of 2023, or $6.93 per share, basic and diluted.

INBX

Inhibrx Q4 Net Income $(47.9)M Or $(3.09) Per Share

SANA

Sana Biotechnology Q4 2024 Adj. EPS $(0.23), Inline

Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) reported quarterly sales of $94.200 million which missed the analyst consensus estimate of $95.450 million by 1.31 percent. This is a 20.96 percent decrease over sales of $119.184 million the same period last year.

HNRG

Hallador Energy Q4 Sales $94.200M Miss $95.450M Estimate

Believes Proposed Transaction with Akoya Significantly Undervalues Quanterix
Encourages Shareholders to Vote Against Transaction to Protect Long-Term Value of their Investment
Kent Lake PR LLC ("Kent Lake") is a holder of 7.47% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>). Kent Lake has previously issued a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkentlake.s3.us-west-1.amazonaws.com%2FQTRX-AKYA_KLPRVoteNoDeck.pdf&amp;esheet=54224976&amp;newsitemid=20250317350313&amp;lan=en-US&amp;anchor=public+presentation&amp;index=1&amp;md5=3d2874e92fe780ca61d1f0c55f02e042">public presentation</a> detailing its opposition to the Company's proposed transaction (the "Transaction") with Akoya Biosciences ("Akoya") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>), and has also <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20250302423208%2Fen%2FKent-Lake-Nominates-Three-Highly-Qualified-Independent-Candidates-for-Quanterix-Board&amp;esheet=54224976&amp;newsitemid=20250317350313&amp;lan=en-US&amp;anchor=nominated&amp;index=2&amp;md5=ce02c5314a931458300c987ca9fdfcab">nominated</a> three highly qualified, independent candidates for election to the Company's Board of Directors (the "Board").
Kent Lake urges Quanterix management to address the following questions related to the Transaction on its earnings call today:
<ul>
<li>Disproportionate Value Distribution: Why does Quanterix continue to pursue a transaction that allocates over 82% of the combined company enterprise value to Akoya shareholders and less than 18% to Quanterix shareholders?</li>
<li>Akoya Going Concern: When evaluating Akoya's liquidity and going concern issues, as well as its potential impact on Quanterix shareholders' value, what key findings and assumptions did the Quanterix Board review and rely on to inform their M&amp;A evaluation and approve the terms of this merger, which awards Akoya shareholders a significant valuation premium on all metrics compared to Quanterix shareholders in spite of Akoya's going concern disclosures?</li>
<li>Conflicts of Interest: To what extent was Dr. Ivana Magovčević-Liebisch allowed to attend meetings, participate in discussions, and vote on matters related to the Akoya merger, despite her conflict of interest as a Board member at Akoya's key commercial diagnostic partner?</li>
<li>Material NIH Risk: Given that uncertainty around National Institutes of Health ("NIH") funding has led to a significant revaluation across the sector, and this uncertainty is material enough for peer companies to begin including new NIH-related risk factor disclosures in their FY 2024 10-K filings, how can Quanterix shareholders reasonably rely on the forward-looking statements, financial projections, fairness opinions, and purported merger benefits being presented that don't account for or contemplate this new material risk?</li>
<li>Akoya's Process: Given the S-4 discloses that Quanterix was bidding against itself by the end of the process, and that all other bidders had already walked away without making final offers due to concerning issues such as Akoya's high cash burn and debt, how is the Quanterix Board integrating this information into their fiduciary framework to continue to recommend the Merger?</li>
<li>The Board's Recommendation: Considering these outstanding issues and insufficient disclosures, what steps does the Quanterix Board plan to take to ensure they are fulfilling their fiduciary duties and are not required to withdraw their Merger recommendation?</li>
</ul>

Management

AKYA

QTRX

Kent Lake Urges Quanterix Management To Address Key Questions Regarding Its Proposed Transaction With Akoya Biosciences; Believes Proposed Transaction With Akoya Significantly Undervalues Quanterix; Encourages Shareholders To Vote Against Transaction To Protect Long-term Value Of Their Investment

GETY

Getty Images Sees FY25 Revenue $918M-$955M Vs $954.667M Estimate; Sees Adj. EBITDA $272M-$290M

FGEN

FibroGen Q4 EPS From Continuing Operations $(0.08), Revenue From Continuing Operations $3.100M

Contracts

ICFI

ICF Secures Multiple Utility Demand-side Energy Management Contracts Valued At Over $35M To Deliver Its Residential And Commercial Demand-side Management Programs

Two insiders of Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) sold large blocks of DJT shares last week, according to SEC filings. Here's a look at the details of the<a href="https://www.benzinga.com/general/social-media/24/11/41993328/trump-media-insiders-sell-more-than-16-million-in-djt-stock"> insider transactions.&nbsp;</a>
The Details: Trump Media CFO and treasurer Phillip Juhan sold approximately 21,000 shares in transactions totaling more than $431,000, according to a Form 4<a href="https://www.sec.gov/Archives/edgar/data/1808488/000147450625000055/xslF345X05/primary_doc.xml"> filing</a>. The sales were part of Juhan's previously <a href="https://www.sec.gov/Archives/edgar/data/1849635/000114036124045278/ef20038154_424b3.htm">disclosed</a> trading plan to sell 400,000 Trump Media &amp; Technology shares by December 2025.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/travel/25/03/44359238/severe-storm-system-brings-devastation-at-least-42-dead-power-outages-widespread-damage-reported">Severe Storm System Brings Devastation: At Least 42 Dead, Power Outages, Widespread Damage Reported&nbsp;</a>
Juhan still holds 220,577 shares of DJT, according to the filing, most of which are restricted stock units (RSUs) <a href="https://www.sec.gov/Archives/edgar/data/1849635/000147450624000234/xslF345X05/primary_doc.xml">awarded </a>to him on Nov. 5 that cannot be immediately sold.
One-quarter of Juhan&#8217;s restricted stock units became eligible for sale on Dec. 25, 2024, and the remaining shares will vest in quarterly installments through March 2027.
Eric Swider, TMTG director, sold 15,000 shares of DJT last week in transactions totaling nearly $300,000, according to his Form 4 <a href="https://www.sec.gov/Archives/edgar/data/1836937/000147450625000056/xslF345X05/primary_doc.xml">filing</a>. The filing also shows that on Feb. 25, 2025 18,043 Trump Media shares were transferred to Swider from Renatus LLC, a company he controls. 
Swider still owns 28,989 shares of Trump Media, some of which are restricted stock units that will vest according to the same schedule as Juhan's RSUs.&nbsp;
What Else: Trump Media &amp; Technology shares<a href="https://www.benzinga.com/general/social-media/25/03/44286296/trump-media-technology-stock-drops-50-since-inauguration-day"> have fallen</a> nearly 50% since President Donald Trump returned to the White House. inauguration. On Jan. 17, 2025, the last trading day before Trump's inauguration, the stock closed at $40.03.
The company, which is the parent of Trump&#8217;s Truth Social platform, will likely release its fourth-quarter results sometime in March, though an exact date has not been confirmed by the company.&nbsp;
DJT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Trump Media &amp; Technology Group shares were up 2.18% at $20.65 heading into Monday's closing bell.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44310724/doge-cuts-to-ftc-sow-confusion-in-case-against-amazon">DOGE Cuts To FTC Sow Confusion In Case Against Amazon</a>&nbsp;</li>
</ul>
Image: Shutterstock&nbsp;

Social Media

Insider Trades

General

Trump Media & Technology Insiders Dump Shares

Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 50 percent. This is a 33.33 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $247.30 million which beat the analyst consensus estimate of $246.31 million by 0.40 percent. This is a 9.45 percent increase over sales of $225.94 million the same period last year.

Getty Images Holdings Q4 2024 GAAP EPS $0.06 Beats $0.04 Estimate, Sales $247.30M Beat $246.31M Estimate

This Milestone Reflects the Company's Commitment to be a Strategic Partner for U.S. Government Customers
Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), a leading provider of team collaboration and productivity software, today announced that Atlassian Government Cloud has received Federal Risk and Authorization Management Program (FedRAMP) authorization at the Moderate level. FedRAMP is a U.S. government program that promotes the adoption of cloud technologies across the federal government by providing a standardized approach to validating security and risk controls for cloud-based products and services.

TEAM

Atlassian Achieves FedRAMP Moderate Authorization For Atlassian Government Cloud; Milestone Reflects The Company's Commitment To Be A Strategic Partner For U.S. Government Customers

Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) reported quarterly losses of $(2.43) per share which beat the analyst consensus estimate of $(2.69) by 9.67 percent. This is a 15.71 percent decrease over losses of $(2.10) per share from the same period last year.

RBOT

Vicarious Surgical Q4 2024 Adj. EPS $(2.43) Beats $(2.69) Estimate

Press Releases

LifeStance Reports Second Quarter 2024 Results

Legal

Bragar Eagel & Squire, P.C. Is Investigating LifeStance and Customers Bancorp and Encourages Investors to Contact the Firm

LifeStance to Present at the 22nd Annual Morgan Stanley Healthcare Conference

LifeStance Survey Finds 79% of Americans Are Experiencing Anxiety Over the 2024 U.S. Presidential Election

LifeStance to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024

LifeStance Reports Third Quarter 2024 Results

Financing

Zarminali Health Launches with $40M in Seed Funding to Transform Pediatric Care through Nationwide, Multi-specialty Practice Group

LifeStance to Host Fourth Quarter and Full Year 2024 Earnings Conference Call on February 27, 2025

LifeStance Reports Fourth Quarter and Full Year 2024 Results

LifeStance Appoints Dave Bourdon as CEO; Ken Burdick Named Executive Chairman

CUBI

LFST

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

LifeStance Health Gr

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL